| Literature DB >> 33377124 |
David G P van IJzendoorn1, Daniela C F Salvatori2, Xu Cao3, Francijna van den Hil3, Inge H Briaire-de Bruijn1, Danielle de Jong4, Hailiang Mei5, Christine L Mummery3, Karoly Szuhai4, Judith V M G Bovée1, Valeria V Orlova3.
Abstract
Chromosomal translocations are prevalent among soft tissue tumors, including those of the vasculature such as pseudomyogenic hemangioendothelioma (PHE). PHE shows endothelial cell (EC) features and has a tumor-specific t(7;19)(q22;q13) SERPINE1-FOSB translocation, but is difficult to study as no primary tumor cell lines have yet been derived. Here, we engineer the PHE chromosomal translocation into human induced pluripotent stem cells (hiPSCs) using CRISPR/Cas9 and differentiate these into ECs (hiPSC-ECs) to address this. Comparison of parental with PHE hiPSC-ECs shows (1) elevated expression of FOSB, (2) higher proliferation and more tube formation but lower endothelial barrier function, (3) invasive growth and abnormal vessel formation in mice after transplantation, and (4) specific transcriptome alterations reflecting PHE and indicating PI3K-Akt and MAPK signaling pathways as possible therapeutic targets. The modified hiPSC-ECs thus recapitulate functional features of PHE and demonstrate how these translocation models can be used to understand tumorigenic mechanisms and identify therapeutic targets.Entities:
Keywords: CRISPR/Cas9-mediated gene targeting; PHE; chromosomal translocation; endothelial cell differentiation; gene fusion; hiPSC-ECs; hiPSC-derived ECs; hiPSCs; human induced pluripotent stem cells; pseudomyogenic hemangioendothelioma; t(7;19)(q22;q13) SERPINE1-FOSB chromosomal translocation; tumor model; vascular tumor
Mesh:
Substances:
Year: 2020 PMID: 33377124 PMCID: PMC7762773 DOI: 10.1016/j.xcrm.2020.100153
Source DB: PubMed Journal: Cell Rep Med ISSN: 2666-3791